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Introduction 
Congenital coagulation Factor VII deficiency is a rare coagulation 
disorder charterised by haemorrhages occurring spontaneously in the 
severely deficient patient or after surgical challenge in those who are 
mildly affected (Mariani et aI., 1978). Factor VII deficiency is 
characteristically inherited in an autosomal recessive manner. The 
frequency of this disorder has been estimated to be one per 500,000 persons 
worldwide. Definitive diagnosis of Factor VII deficiency rests on a 
specific assay for Factor VII coagulant activity (functional analysis), or 
for Factor VII antigen level (immunochemical analysis), or both. 
Functional variants of Factor VII have been described based on different 
reactivity with tissue thromboplastins from several species (Roberts and 
Foster, 1987). 
Factor VII deficiency in Malta was first identified in a single family in 
July 1991. The proband was a girl born in 1987. She had no history of 
bleeding tendency and Factor VII deficiency was diagnosed during pre-
operative coagulation studies prior to tonsillectomy. 
Studies were performed in order to explore the genetic basis of 
coagulation Factor VII deficiency in this Maltese kindred. Factor VII 
coagulant assays were performed on 11 members of the kindred. These 
assays were performed four times on plasma samples from the proband, 
siblings and parents, employing a tissue thromboplastin from a different 
species each time. The thromboplastins were ox, porcine, human and 
rabbit, brain tissue thromboplastin. Factor VII coagulant assays were 
performed once on plasma samples from other members of the kindred, 
employing rabbit brain tissue thromboplastin. 
A molecular probe capable of hybridising with the Factor VII gene and 
suitable for mapping DNA abnormalities of the same gene was 
synthesised. Genomic DNA was isolated from the leukocytes of a 
peripheral blood sample from 16 members of the affected kindred. These 
genomic DNA samples were stored for future analysis utilising the 
synthesised probe. 
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Methodology 
Studyl 
Factor VII Bioassay 
Factor VII coagulant assays were performed on plasma samples using a 
modified one-stage Prothrombin Time test. The modification consisted of 
the use of Factor VII-deficient plasma as substrate plasma, to make the 
test specific for Factor VII. The assays were performed on an automated 
coagulometer (Automated Coagulation LaboratoryTM 300, 
Instrumentation Laboratory). Ox, porcine and human brain tissue 
thromboplastins were prepared by acetone drying of the fresh brain, 
while rabbit brain tissue thromboplastin was purchased from 
Instrumentation Laboratory. 
Study 2 
DNA Studies 
Genomic DNA was isolated by a technique which gently lysed the 
leukocytes and solubilised the DNA, followed by physical methods 
which purified and precipitated the DNA. 
The Factor VII gene probe that was synthesised was 653 base pairs long 
and complementary to a region towards the middle of the Factor VII gene. 
This probe was synthesised by Polymerase Chain Reaction technology, 
which is an in vitro method for the enzymatic synthesis and 
amplification of specific DNA sequences, using two oligonucleotide 
primers that hybridise to opposite strands and flank the region of 
interest in the template DNA. Normal genomic DNA was used as 
template for the synthesis of the Factor VII gene probe. 
The primer pair were selected by the use of primer design software 
(Primer Detective™, Clotech Laboratories Inc.) and were synthesized on 
a DNA synthesizer (Applied Biosystems). The Polymerase Chain 
Reaction was carried out in an automated thermal cycler (DNA Thermal 
Cycler, Perkin-Elmer Cetus). 
The Polymerase Chain Reaction product was positively identified as the 
required probe by determination of its length. This was achieved by 
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electrophoresis of the product and comparison of the position of the 
resulting band with that of PhiX/Hae III marker fragments within the 
gel. The identity of the product was also confirmed by restriction 
endonuclease mapping, employing restriction enzymes which digest the 
expected probe at known sites. 
Results 
Study 1 
Factor Bioassay 
Results of the Factor VII bioassays are shown in Tables 1 and 2. The 
pedigree of the proband and her relatives is shown in Figure 1. 
Table 1: Results of Factor VII coagulant assays with a panel of tissue 
thromboplastins from different species, on plasma from proband, 
siblings and parents. Results of Factor VII coagulant activity 
below that of the normal control are shown in bold print. 
No Subject Factor VII Coagulant Activity with Various 
Thromboplastins (%) 
Rabbit Human Ox Brain Porcine 
Brain Brain thrombo- brain 
thrombo- Thrombo- plastin Thrombo-
plastin plaslin plastin 
1 Proband 12 3 2 2 
2 Father 27 12 4 8 
3 Mother 45 46 40 40 
4 Sister 46 38 20 31 
5 Brother 10 2 1 1 
Normal Control 43 41 18 37 
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I I 
III 
E.A. 
10'1 
I11III Male, homozygote 
!illl Male, carrier 
o Male, uncertain genotype 
• Female, homozygote 
® Female, carrier 
o Female, uncertain genotype 
FigUIe 1: Pedigree of proband and her relatives. Percentages correspond. 
to Factor VII Coagulant Activity (with rabbit brain tissue 
thromboplastin) 
Table 2: Results of Factor VII coagulant assays with rabbit brain tissue 
thromboplastin, on plasma' from members of the kindred 
(namely grandparents, aunts and uncles of proband). Result of 
Factor VII coagulant activity below that of the normal control is 
shown in bold print. 
No 
6 
7 
8 
9 
10 
11 
Subject 
Initials 
A.B. 
J.B. 
F.B. 
F.A. 
M.A. 
E.A. 
Factor VII Coagulant activity with Rabbit 
Brain Thromboplastin 
% 
Normal Control 
38 
83 
87 
76 
67 
80 
52 
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Study 2 
DNA Studies 
The syrithesised Factor VII gene probe (653 bp) can be seen in Figure 2 as a 
band located slightly above the 603 bp fragment of the PhiX/Hae III 
marker. 
RestriCtion endonuclease mapping confirmed the identity of the 
synthesised probe, since fragments of expected length were produced. 
,X174 DNA/file m 
1353 bp 
1078 bp 
872bp 
603bp 
1 2 
653bp product 
Primers 
3 4 
Figure 2: Agarose gel analysis of the product of the Polymerase Chain 
Reaction product. Lane 1 includes Hae III-digested PHiX 174 
DNA as ·marker. Lanes 2, 3 and 4 include the product of the 
Polymerase Chain Reaction (the 653 bp probe). 
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Discussion 
This study represents an initial approach to the characterisation of the 
functional defect and its molecular basis, causing hereditary Factor VII 
deficiency in this kindred. 
While bioassay studies provide basis for understanding structure-function 
relationships in the Factor VII protein, DNA studies provide information 
on the molecular deficiency at the DNA level. 
Such studies also form the basis for diagnosis and carrier detection of 
family members and provide the necessary information for counselling. 
Additionally, by understanding the mechanism of the disease, future 
therapeutic intervention may be possible. 
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